Immunicum AB (publ) Announces Update on Survival Data from Phase II MERECA Trial of Ilixadencel in Kidney Cancer

NEXT STORY
Lori Grant Named CEO of Klick Health as Klick Group Also Expands with Two New Companies
PREV STORY
BriaCell Therapeutics Corp. Announces Completion of Shares for Debt Issuance
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Heat Biologics to Present at the American Association for Cancer Research (AACR) Annual Meeting

DURHAM, N.C., March 02, 2017 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. (“Heat”) (Nasdaq:HTBX), a ...

author_avatar
NASDAQ Market News

Results from Oasmia Pharmaceutical’s phase III study have been presented at ASCO annual meeting

During Monday Oasmia Pharmaceutical AB presented the follow-up results from the completed phase III ...

author_avatar
NASDAQ Market News

ICU Medical, Inc. to Present at 34th Annual J.P. Morgan Healthcare Conference

SAN CLEMENTE, Calif., Jan. 04, 2016 (GLOBE NEWSWIRE) -- ICU Medical, Inc. (Nasdaq:ICUI), a ...

author_avatar
NASDAQ Market News